Glial Cells and myelination Flashcards

1
Q

CNS neural cells

A

neurons (signalling)
glia (astrocytes,OL,microglia)
formed from multipotent neural SC

microglia derived from peripheral myeloid cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

roles of glia

A

development
structural
nutrition (OL/astrocytes for lactate and glucose)
injury
glial scar
phagocytosis (microglia)
myelination (OL)
homeostasis (K+ release/NT removal)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what does the brain contain

A

50% white matter (CC)
50% grey matter

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

why do signals decay along an axon

A

membrane resistant Rm
axial resistance Ri
membrane capacitance Cm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

length constant and time constant

A

length constant = sqrt(Rm/Ri)
time constant = t=RmCm

decrease in Cm - increases time constant/AP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

myelin G factor/ratio

A

d1 (axon only)/d2 (axon+myelin)

0.5-0.9
optimal = 0.77

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

myelinated vs unmyelinated axons

A

unmyelinated - faster if axon <1um, many NaV/KV
myelinated - faster if axon >1um, less energy used, lots of NaV/pumps/nodes/internodes, saltatory conduction, occupies less space than myelinated ones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Schwann cells (PNS glia)

A

1 internode - myelinate a single axon
form non-myelinating Ramak Bundles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

myelin sheath

A

evolved independently (dog/prawn/earthworm)
concentric lamellae /fatty insulating layer/saltatory conduction
paranode - node - paranode structure paranode contains cytosol
caspr/contactin/NF155 needed for node formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

myelin composition

A

lipids: cholesterol (27%) synthesis greatest during development , needed throughout life
glycosphingolipids (31%) GalC, used to identify OLs

proteins: 30% fuse and stabilise lamellae, mediate membrane-membrane interactions between myelin lamellae, axons and myelin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

types of myelin proteins

A

MBP - fusion of cytoplasmic interface
PLP - fusion of extracellular face of myelin lamellae mutant: myelin unravelling, PMD,leukodystrophy
CNPase (cyclic nucleotide phosphodiesterase) - enzyme specific to OLs, metabolises cAMP, increases adenosine (neuroprotectant) KO - axon degeneration, myelin is unaltered

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what does a loss of myelin cause

A

axon dysfunction and degeneration
(MS and other neuropathies)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what are OLs derived from

A

NG2/OPC/polydendrocytes
needed for cognition and motor skills
from birth throughout life

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what does motor skill learning require

A

active central myelination (produces new OLs)
OPCs present densely in the hippocampus (learning site)

coexpress NG2 (Cspg4/Pdgfr) susceptible to hypoxia damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

signalling which causes myelination

A

communication via neuro-glial signalling molecules (gliotransmitters): 1)attract OPCs 2) proliferation 3) myelination
axon-OPC (direct) astrocytes (indirect)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

NTs which affect myelination

A

adenosine (differentiation and myelination)
ATP
GABA (inhibits differentiation)
glutamate (promotes differentiation)
DA
ACh
BDNF promotes differentiation of myelin by stimulating the proliferation of OPCs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Growth factors which affect myelination

A

PDGF-AA/FGF2 (essential for OPC differentiation)
Wnt/BMP/Notch inhibit OPC differentiation
IGFI stimulates differentiation
Nrg1-Erb regulates myelination

18
Q

decline in generation of OLs

A

at 60 ~100% have at least one WM lesion
at 70 - 1-10 WM lesions
WM shrinks after 50 yrs
decreased myelin replacement through natural wear and tear

19
Q

developmental myelin pathologies

A

leukodystrophies (genetic cause)
cerebral palsy

both cause a loss of WM around the ventricles

20
Q

myelin damage causes…

A

brain injury
infection
toxin
ischaemia/stroke
dementia
bipolar disease
ASD
schizophrenia

21
Q

diseases which cause demyelination

A

MS
acute disseminated encephalomyelitis
Guilliane Barres Syndrome

22
Q

symptoms of myelin loss

A

impaired vision (optic nerve is where demyelination is first seen)
impaired hearing
memory loss
loss of dexterity

23
Q

who gets MS

A

1 in 1000 in the UK
females are more likely
age range: 15-50
mean onset: 28m 33f
prognosis: LT
5-10yrs reduced lifespan

24
Q

what is MS

A

autoimmune disease
where the immune cells attack myelin
demyelination occurs in flares (relapses) then remyelination occurs (complete but thin and risk of failing)

25
Q

genetic and environmental factors which cause MS

A

HLA class II gene (susceptibility gene)
associated gene: APOE/CNTF/osteopontin

environmental: EBV (after 15yrs) systemic infections

26
Q

MS pathogenesis

A

relapsing/remitting (90%) - periods of demyelination followed by partial remyelination
primary progressive (10%) - demyelination becomes more widespread and patient deteriorates slowly with no remission - astrocyte scarring and failure of remyelination

27
Q

physical MS pathogenesis

A

CNS lesions in the SC causes numbness and weakness
optic nerve degeneration causes visual disturbances
cerebellum - ataxia/BS vertigo
no cure but therapies ameliorate symptoms

28
Q

MS phases

A

preclinical
demyelination
remyelination
inactive/chronic demyelinating plaque

29
Q

preclinical stage of MS

A

early phase lesion formed w/o clinical signs
depends on immune cells crossing BBB
triggers microglial activation without demyelination

30
Q

microglia

A

distributed in mosaic pattern throughout CNS
5% all brain cells
phagocytic/immune cells
express many receptors (ON/OFF) - cellular damage releases ATP (microglia contain ATP R)

31
Q

microglia activation states

A

M1 classically activated (proinflammatory, release TNFa/NO) associated with acute infection- damage OL/myelin
M2 alternatively activated (anti-inflammatory - associated with tissue remodelling) releases FGF2 which promotes remodelling
but…multiple intermediate phases

32
Q

4 patterns of MS lesions (demyelination)

A

I - inflammatory cell infiltrate (macrophages B/T cells)
II - like pattern I lesions (added with complement and antibodies)
III - oligodendrocyte apoptosis little infiltration, macrophages are present
IV - 1% of lesions, OL death (non-apoptotic)

33
Q

remyelination

A

thinner myelin and sheaths
requires adult OPCs (co-express NG2 - Cspg4) and Pdgfra

34
Q

inactive/chronic demyelinating plaque

A

inside plaque there is a loss of myelin and OLs
plaques are acellular with few glia (small/fibrous astrocytes)
dense astrocytic gliosis

35
Q

why does remyelination fail

A

decline in OL regeneration
loss of replacement of myelin
MS neurodegeneration - due to a lack of GF? Pdgf-aa FGF2 or inhibitory factors? Notch/wnt/bmp/astrocytic scars

36
Q

Licensed MS drugs

A

B-interferon - reduces and prevents inflammation (e.g. Avonex)
Copaxone/glatiramer acetate - myelin decoy for the immune system (polymer of 4aa in MBP), reduces immune cell entry (e.g. Tysabri)

37
Q

drugs in current trials to treat MS

A

monoclonal antibodies (Daclizumab - targets CD25 on immune cells)/Rituximab (targets CD20 on Bcells)
anti-inflammatory drugs (Minocycline/simvastin for secondary progressive MS)
Anti-viral (Raltegravir)
Metformin - stimulates myelination by mimicking fasting (reduces blood sugar)

38
Q

future therapies

A

phase II - anti-LINGO used in myelin repair
stem cell therapy - obtain haematopoietic SC - chemotherapy (remove immune cells) inject SC - isolation (only used in severe MS)

39
Q

TRPA1

A

non-specific cation channel (Ca2+ permeable)
activated during ischaemia (stroke/low O2/glucose)
damages myelin
constitutively active and regulates the excitability of axons
agonists - decrease amplitude of compound action potential

40
Q

TRPA1 antagonists

A

FFA
increase Ca2+ increases amplitude of compound AP (measure CAPs in adult optic nerve - Lajoso et al)
prevents WM loss